Erratum: Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets? (Journal of Bone and Mineral Research (2012) 27:11 (2238-2241) DOI: 10.1002/jbmr.1753);Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets?

Journal of Bone and Mineral Research

Volumn 27, Issue 11, 2012, Pages 2238-2241

  Cooper, Mark S ^a   Zhou, Hong ^b   Seibel, Markus J ^b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Geriatric Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; COMPOUND A; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HERBACEOUS AGENT; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PARATHYROID HORMONE[1-34]; PREDNISOLONE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE INJURY; CELL DIFFERENTIATION; CELL PROLIFERATION; CORTICOSTEROID THERAPY; GLUCOSE INTOLERANCE; HUMAN; MORPHOMETRICS; NONHUMAN; NOTE; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROMA CELL; SYNOVIOCYTE;

EID: 84867525648     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1806     Document Type: Erratum

References (32)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF., The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clinic Proc. 1949; 24 (8): 181-97.
2. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C., Use of oral corticosteroids and risk of fractures. J Bone Mine Res. 2000; 15 (6): 993-1000. (Pubitemid 30350061)
3. Ramsey-Goldman R., Missed opportunities in physician management of glucocorticoid-induced osteoporosis ? Arthritis Rheum. 2002; 46 (12): 3115-20. (Pubitemid 35453519)
4. Walsh LJ, Wong CA, Pringle M, Tattersfield AE., Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996; 313 (7053): 344-6. (Pubitemid 26334822)
5. Adinoff AD, Hollister JR., Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983; 309 (5): 265-8. (Pubitemid 13074917)
6. Turner RT, Hannon KS, Greene VS, Bell NH., Prednisone inhibits formation of cortical bone in sham-operated and ovariectomized female rats. Calcif Tissue Int. 1995; 56 (4): 311-5.
7. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P., Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996; 81 (5): 1740-6. (Pubitemid 26152456)
8. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, Mancini D, Michler RE, Aaronson K, Addesso V, Lo SH., Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997; 82 (5): 1497-506. (Pubitemid 27200425)
9. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S., Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140 (10): 4382-9. (Pubitemid 30666099)
10. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS., Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145 (4): 1835-41. (Pubitemid 38402392)
11. Henneicke H, Herrmann M, Kalak R, Brennan-Speranza TC, Heinevetter U, Bertollo N, Day RE, Huscher D, Buttgereit F, Dunstan CR, Seibel MJ, Zhou H., Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone. 2011; 49 (4): 733-42.
12. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG., Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339 (5): 292-9. (Pubitemid 28366417)
13. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP., Marcus R Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357 (20): 2028-39. (Pubitemid 350106710)
14. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN., Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373 (9671): 1253-63.
15. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA., Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67 (4): 277-85.
16. Kassel O, Herrlich P., Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol. 2007; 275 (1-2): 13-29. (Pubitemid 47259283)
17. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR., DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009; 324 407-10.
18. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G., Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001; 20 (24): 7168-73. (Pubitemid 34062308)
19. Robertson S, Allie-Reid F, Vanden Berghe W, Visser K, Binder A, Africander D, Vismer M, De Bosscher K, Hapgood J, Haegeman G, Louw A., Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of Compound A. J Biol Chem. 2010; 285 (11): 8061-75.
20. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G., Glucocorticoid-mediated repression of nuclear factor-kappaB- dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci U S A. 1997; 94 (25): 13504-9. (Pubitemid 28009612)
21. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Muller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G, Elewaut D., A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol. 2008; 180 (4): 2608-15.
22. Gossye V, Elewaut D, Bougarne N, Bracke D, Van Calenbergh S, Haegeman G, De Bosscher K., Differential mechanism of NF-kappaB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2009; 60 (11): 3241-50.
23. Wust S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, van den Brandt J, Luhder F, Reichardt HM., Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PloS One. 2009; 4 (12): e8202.
24. Zhang Z, Zhang ZY, Schluesener HJ., Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol. 2009; 183 (5): 3081-91.
25. Rauner M, Goettsch C, Stein N, Thiele S, Bornhaeuser M, De Bosscher K, Haegeman G, Tuckermann J, Hofbauer LC., Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology. 2011; 152 (1): 103-12.
26. Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, Rauner M., Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Mineral Res. 2012; 27: 2242-2250.
27. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David JP, Reichardt HM, Amling M, Schutz G, Tuckermann JP., Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010; 11 (6): 517-31.
28. Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K, Vandooren B, Rauner M, Hofbauer LC, Haegeman G, Elewaut D, Tuckermann JP, De Bosscher K., An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 2011; 25 (4): 1323-32.
29. Vattakuzhi Y, Abraham SM, Freidin A, Clark AR, Horwood NJ., Dual-specificity phosphatase 1-null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis. Arthritis Rheum. 2012; 64 (7): 2201-10.
30. Baschant U, Frappart L, Rauchhaus U, Bruns L, Reichardt HM, Kamradt T, Brauer R, Tuckermann JP., Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci U S A. 2011; 108 (48): 19317-22.
31. Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, Straub RH, Modzelewski J, Dunstan CR, Seibel MJ., Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum. 2009; 60 (7): 1998-2007.
32. Hardy R, Cooper MS., Bone loss in inflammatory disorders. J Endocrinol. 2009; 201 (3): 309-20.